Letter to the Editor: A response to Hruska’s case study on molecular breast imaging and the need for true tissue quantification

FMTVDM Study Proposal: WID2H - Breast Trial. (Weight, Inflammation, Diet v Drug, Heart disease) – Breast Trial

“…That which makes cancer, cancer, and that, which makes transitional changes in cells/tissue different from cancer and normal tissue, is what we must be able to measure if we are to address the health risk associated with the number one cause of morbidity and mortality worldwide. We cannot address cancer or its treatment, without the ability to measure these changes [41][42][43][44].…”

Proposed Breast Lump (FMTVDM/BEST) Pathway Nuclear Imaging Protocol

“…As such FMTVDM not only finds the presence and absence of cancer but it can "measure" (quantify) these transitional states. The consequence of being able to "measure" these transitional changes, provides an accurate, consistent and reproducible method to monitor change over time, including treatment effects [6][7][8] in both men [9] and women, women with dense breasts [10] and the ability to find and measure secondary cancers being suppressed by primary cancers [11], alerting clinicians to the presence of the secondary cancer and the need for treatment directed at the secondary cancer, sooner than later. We propose the use of the Breast Lump Pathway Protocol and its comparison with the alternative multi step approach currently being used in the evaluation and treatment recommendations currently employed.…”

Virtual Quantification is Not True Quantification: FMTVDM-TFM©℗ Provides True Quantification for SPECT and PET

“…As recently presented [4] and as published [5][6][7][8][9], for our scintillation tools to be accurate, consistent and reproducible around the world, you must calibrate these tools to a known standard.…”

“…Zhao reported on a point source for the SPECT camera using a 128 × 128 matrix. Figure 1 slides were presented at the 2018 Florida Society of Nuclear Medicine Technology meeting on 6 May 2018 [4].…”